Get the Stockscreener App
27.87
0.54%
0.15
After Hours:
29.63
1.76
+6.32%
Tg Therapeutics Inc stock is traded at $27.87, with a volume of 3.24M.
It is up +0.54% in the last 24 hours and down -11.10% over the past month.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
See More
Previous Close:
$27.72
Open:
$27.65
24h Volume:
3.24M
Relative Volume:
1.79
Market Cap:
$4.42B
Revenue:
$264.79M
Net Income/Loss:
$-14.36M
P/E Ratio:
-253.36
EPS:
-0.11
Net Cash Flow:
$-28.11M
1W Performance:
-5.24%
1M Performance:
-11.10%
6M Performance:
-24.85%
1Y Performance:
+0.72%
1-Day Range:
$26.89
$28.91
1-Week Range:
$26.89
$30.90
52-Week Range:
$25.28
$46.48
Tg Therapeutics Inc Stock (TGTX) Company Profile
Name
Tg Therapeutics Inc
Sector
Industry
Phone
(212) 554-4484
Address
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Compare TGTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
27.87 | 4.40B | 264.79M | -14.36M | -28.11M | -0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.67 | 116.86B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
758.91 | 80.72B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
810.51 | 49.26B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
369.96 | 49.00B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
351.06 | 36.96B | 4.98B | 69.59M | 525.67M | 0.5197 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-06-25 | Resumed | H.C. Wainwright | Buy |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Oct-29-24 | Initiated | TD Cowen | Buy |
| Aug-02-23 | Upgrade | Goldman | Sell → Neutral |
| Jun-26-23 | Resumed | Jefferies | Buy |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Nov-15-21 | Downgrade | Goldman | Neutral → Sell |
| Apr-20-21 | Initiated | Goldman | Neutral |
| Apr-19-21 | Reiterated | H.C. Wainwright | Buy |
| Sep-01-20 | Initiated | JP Morgan | Overweight |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Initiated | Evercore ISI | Outperform |
| Jan-17-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Feb-06-19 | Resumed | Jefferies | Buy |
| Sep-25-18 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-09-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-01-17 | Resumed | B. Riley FBR, Inc. | Buy |
| Nov-14-17 | Resumed | H.C. Wainwright | Buy |
| Apr-25-17 | Initiated | Jefferies | Buy |
| Mar-06-17 | Reiterated | FBR & Co. | Outperform |
| Oct-06-16 | Resumed | Brean Capital | Buy |
| May-27-16 | Initiated | SunTrust | Buy |
| Dec-01-15 | Initiated | FBR Capital | Outperform |
| Sep-09-15 | Initiated | Raymond James | Strong Buy |
| Aug-12-15 | Resumed | H.C. Wainwright | Buy |
| Jun-19-15 | Reiterated | Brean Capital | Buy |
| Dec-11-14 | Reiterated | ROTH Capital | Buy |
| Dec-10-14 | Reiterated | ROTH Capital | Buy |
View All
Tg Therapeutics Inc Stock (TGTX) Latest News
MS drug maker TG Therapeutics targets $900M in 2026 sales, trial data ahead - Stock Titan
Aug PostEarnings: Is TG Therapeutics Inc still a buy after recent gains2025 Buyback Activity & Safe Capital Investment Plans - baoquankhu1.vn
TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise - MSN
TG Therapeutics stock slid nearly 7% Friday — what to watch next week for TGTX - TechStock²
Market Leaders: Why TG Therapeutics Inc. stock is in analyst buy zone2025 Major Catalysts & Proven Capital Preservation Methods - Улправда
TG Therapeutics (TGTX) stock drops 7% as JPMorgan healthcare conference nears — what investors watch next - TechStock²
How TG Therapeutics Inc. stock performs in stagflationDividend Hike & Target Return Focused Picks - Улправда
Will TG Therapeutics Inc. (NKB2) stock outperform global peers2025 Earnings Surprises & Low Risk Investment Opportunities - Улправда
TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
TG Therapeutics, Inc. (TGTX) Stock Analysis: Strong Buy Ratings and 51.25% Upside Potential - DirectorsTalk Interviews
Is TG Therapeutics Inc a good long term investmentBear Market Strategies & Follow Top Performers in the Community - earlytimes.in
Retail Bets TG Therapeutics Stock Can Sustain Post-Earnings Gains Throughout The Week - MSN
Discipline and Rules-Based Execution in TGTX Response - Stock Traders Daily
TG Therapeutics: What Wall Street Isn't Telling You (NASDAQ:TGTX) - Seeking Alpha
Why TG Therapeutics Stock Was Soaring This Week - MSN
Could The Market Be Wrong About TG Therapeutics, Inc. (NASDAQ:TGTX) Given Its Attractive Financial Prospects? - simplywall.st
Investing in TG Therapeutics (NASDAQ:TGTX) three years ago would have delivered you a 160% gain - Yahoo Finance
TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Osaic Holdings Inc. Sells 39,445 Shares of TG Therapeutics, Inc. $TGTX - MarketBeat
TG Therapeutics Earnings Notes - Trefis
Trading the Move, Not the Narrative: (TGTX) Edition - Stock Traders Daily
Is the options market predicting a spike in TG Therapeutics stock? - MSN
TG Therapeutics (MIL:1TGTX) EV-to-OCF : -66.83 (As of Dec. 22, 2025) - GuruFocus
TG Therapeutics (STU:NKB2) EV-to-FCF : -66.70 (As of Dec. 21, 2025) - GuruFocus
TG Therapeutics (STU:NKB2) EV-to-OCF : -66.83 (As of Dec. 21, 2025) - GuruFocus
Will TG Therapeutics Inc. stock remain a Wall Street favorite2025 Support & Resistance & Consistent Profit Trading Strategies - Улправда
Can TG Therapeutics Inc. stock surprise with earnings upsideQuarterly Earnings Report & Technical Pattern Based Signals - Улправда
Can TG Therapeutics Inc. stock sustain institutional interest2025 Market Overview & Short-Term Trading Alerts - DonanımHaber
Is the Options Market Predicting a Spike in TG Therapeutics Stock? - Zacks Investment Research
How buybacks impact TG Therapeutics Inc. stock valueTrade Risk Report & Free Risk Controlled Daily Trade Plans - Улправда
Can TG Therapeutics Inc. stock resist sector downturns2025 Earnings Surprises & Daily Profit Maximizing Tips - Улправда
Is TG Therapeutics Inc. (NKB2) stock expanding market penetration2025 Trade Ideas & AI Forecasted Entry and Exit Points - ulpravda.ru
Why TG Therapeutics Inc. stock is in analyst buy zoneJuly 2025 Summary & Expert-Curated Trade Recommendations - Улправда
Earnings Recap: Why TG Therapeutics Inc. stock is in analyst buy zoneJuly 2025 Snapshot & Risk Controlled Stock Alerts - Улправда
Will TG Therapeutics Inc. stock benefit from automationMarket Activity Report & Free Expert Verified Stock Movement Alerts - Улправда
Why TG Therapeutics Inc. stock remains on watchlistsJuly 2025 Highlights & Community Driven Trade Alerts - Улправда
TG Therapeutics (TGTX) Lags Q1 Earnings Estimates - sharewise.com
Marex Group plc Makes New $10.02 Million Investment in TG Therapeutics, Inc. $TGTX - MarketBeat
TG Therapeutics (NASDAQ:TGTX) Rating Increased to Buy at Wall Street Zen - MarketBeat
Eventide Asset Management LLC Increases Holdings in TG Therapeutics, Inc. $TGTX - MarketBeat
(TGTX) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Norges Bank Makes New Investment in TG Therapeutics, Inc. $TGTX - MarketBeat
TG Therapeutics, Inc. $TGTX Shares Bought by Diadema Partners LP - MarketBeat
TG Therapeutics, Inc. $TGTX Shares Acquired by Jump Financial LLC - MarketBeat
Is TG Therapeutics (TGTX) Quietly Reframing Its Investment Story Around Neurology Depth Over Breadth? - Sahm
1832 Asset Management L.P. Has $5.18 Million Stock Holdings in TG Therapeutics, Inc. $TGTX - MarketBeat
TG Therapeutics (NASDAQ:TGTX) Lowered to "Hold" Rating by Wall Street Zen - MarketBeat
Lacklustre Performance Is Driving TG Therapeutics, Inc.'s (NASDAQ:TGTX) Low P/S - 富途牛牛
New York State Common Retirement Fund Boosts Stake in TG Therapeutics, Inc. $TGTX - MarketBeat
TG Therapeutics, Inc. (TGTX) Stock Forecasts - Yahoo Finance
TG Therapeutics, Inc. $TGTX Shares Bought by Russell Investments Group Ltd. - MarketBeat
Tg Therapeutics Inc Stock (TGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.74%
2.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):